EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial

Man Qiao iD, Biqi Zhou, Yiyin Chen iD, Huiying Qiu, Shengli Xue iD, Ying Wang iD, Yue Han, Yanming Zhang, Kourong Miao iD, Jihao Zhou iD, Miao Miao, Xiao Ma und 15 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-00670 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Man Qiao und 26 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The Firs…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Sitagliptin Phosphate, Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This trial evaluated whether the addition of sitagliptin to antithymocyte globulin (ATG)–based prophylaxis reduces the incidence of acute graft-versus-host disease (aGVHD) after alternative donor hematopoietic stem-cell transplantation. METHODS This prospective, multicenter, open-label, randomized trial enrolled patients age 18-60 years with hematologic malignancies who received myeloablative conditioning haploidentical or unrelated donor transplantation. Participants were randomly assigned in a 1:1 ratio to ATG-based prophylaxis (ATG + calcineurin inhibitor + methotrexate + mycophenolate mofetil) with or without sitagliptin (600 mg orally once every 12 hours, days –1 to +14). The primary end point was the cumulative incidence of grade Ⅱ-Ⅳ aGVHD by day +100. RESULTS From December 22, 2021, to June 16, 2023, 190 of the 251 screened patients were enrolled, with a median follow-up of 29.8 (0.7-41.3) months. The sitagliptin group had a significantly lower incidence of grade Ⅱ-Ⅳ aGVHD on day +100 (14.7% v 31.6%; subdistribution hazard ratio [sHR] = 0.41; P = .005). Reduced grade Ⅲ-Ⅳ (6.3% v 18.9%; sHR = 0.30; P = .010) and intestinal aGVHD (12.6% v 29.5%; P = .004) and superior day +180 GVHD-free, relapse-free survival (GRFS; 86.3% v 72.6%; HR = 0.44; P = .016) were also observed. No between-group disparities were detected in 2-year chronic GVHD, nonrelapse mortality, relapse-free/overall survival, or cytomegalovirus/Epstein-Barr virus reactivation; the adverse event profiles were similar. CONCLUSION In this randomized trial, adjunct sitagliptin to ATG-containing prophylaxis significantly reduced the incidence of grade Ⅱ-Ⅳ aGVHD. Reductions in severe and intestinal aGVHD, as well as improved day +180 GRFS, were exploratory observations; no significant benefits were detected for long-term GRFS, overall survival, or RFS, and treatment did not alter the engraftment, relapse, or infection risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseSitagliptin PhosphateHematopoietic Stem Cell TransplantationHematologic NeoplasmsHumansFemaleAdultMaleMiddle AgedAdolescentYoung AdultProspective StudiesImmunosuppressive AgentsAcute DiseaseAntilymphocyte SerumTransplantation Conditioning

Substanzen

Sitagliptin PhosphateImmunosuppressive AgentsAntilymphocyte Serum

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Department of Medicine I, Faculty of Medicine, University Medical Center, University of Freiburg, Freiburg, Germany.
  • Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University and the Second People's Hospital of Huai'an, Huai'an, China.
  • Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, and Jiangsu Clinical Medicine Research Institute, Nanjing, China.
  • Department of Hematology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University and the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.

ORCID-Profile: Man Qiao, Yiyin Chen, Shengli Xue, Ying Wang, Kourong Miao, Jihao Zhou, XiaoJin Wu, Tao You, Xiebing Bao, Zaixiang Tang, Xiaofei Yang, Robert Zeiser, Suning Chen, Yang Xu

Zitieren

APA

Qiao, M., Zhou, B., Chen, Y., Qiu, H., Xue, S., Wang, Y., Han, Y., Zhang, Y., Miao, K., Zhou, J., Miao, M., Ma, X., Wu, X., He, X., Hu, X., Hu, M., Zhu, H., Wang, R., Dai, H., …, & Xu, Y. (2026). Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00670

Vancouver

Qiao M, Zhou B, Chen Y, Qiu H, Xue S, Wang Y, et al. Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00670

BibTeX
@article{Qiao2026,
  author = {Qiao, Man and Zhou, Biqi and Chen, Yiyin and Qiu, Huiying and Xue, Shengli and Wang, Ying and Han, Yue and Zhang, Yanming and Miao, Kourong and Zhou, Jihao and Miao, Miao and Ma, Xiao and Wu, XiaoJin and He, Xuefeng and Hu, Xiaohui and Hu, Mingming and Zhu, Han and Wang, Rongxian and Dai, Haiping and You, Tao and Bao, Xiebing and Tang, Zaixiang and Yang, Xiaofei and Zeiser, Robert and Chen, Suning and Wu, Depei and Xu, Yang},
  title = {Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-00670}
}
Kostenlos starten →